# Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

> **NCT01217931** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 180 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Bevacizumab
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT01217931
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2011-01-19
- **Primary completion:** 2028-01-31
- **Final completion:** 2028-01-31
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01217931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01217931, "Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01217931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*